MGI Tech has reached a milestone in its collaboration with Predica Diagnostics. Predica’s HPV Profiler and CervicaDx assays, based on its proprietary Cirnaseq technology, have been validated and successfully deployed on MGI’s DNBSEQ sequencing platforms, reducing turnaround time from two weeks to one day.
The achievement marks the transition of the partnership from an initial agreement two years ago to real-world impact. Predica has integrated MGI’s DNBSEQ platforms into its internal R&D and commercial service projects, with several labs recieving results faster than on conventional platforms. The validation confirms that laboratories already running DNBSEQ systems can incorporate Predica’s Cirnaseq-based diagnostics into their existing workflows.
MGI’s E25 and G99 sequencers, combined with Predica’s Cirnaseq technology and Cirnalyzer software, provide an affordable, scalable workflow for clinical labs, service providers, and national cervical cancer screening programs.
The integrated solution offers:
-
Automated analysis and reporting through Predica’s Cirnalyzer software
-
Lower cost per sample
-
Simultaneous high-resolution HPV genotyping and host-gene expression profiling
-
Improved specificity for cervical cancer risk assessment and HPV+ triage
Predica’s team used the platform to run side-by-side comparisons of different library preparation conditions, identifying the optimal protocol for the Cirnaseq platform. This iterative optimisation used to take months, but can now be completed within days.
Dr William Leenders, CSO of Predica Diagnostics, said, “By combining our Cirnaseq assays with MGI’s sequencing technology, we’re enabling labs to access deeper biological insights at a fraction of the cost. This is part of our mission to improve women’s health.”
Dr Fang Cheng, general manager of Europe and Africa at MGI, said, “By running Predica’s Cirnaseq assays on our DNBSEQ platforms, we’re proving that high-accuracy cancer diagnostics doesn’t have to come with a high price tag or slow turnaround. For the millions of women waiting on cervical cancer screening results, faster turnaround means less anxiety and faster treatment. That’s the impact we’re proud to enable.”
MGI and Predica will jointly validate assays, develop native DNBSEQ library preparation kits, and prepare for IVDR submissions. Initial market focus will be on Europe and Africa, with global expansion to follow.
